Russell Frank Company’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Russell Frank Company’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-24,343	Closed	-$743K	–	3057
2015 Q4	$743K	Buy	24,343 +4,216	+21%	+$149K	﹤0.01%	2333
2015 Q3	$693K	Sell	20,127 -13,647	-40%	-$413K	﹤0.01%	2361
2015 Q2	$1.06M	Buy	+33,774	New	+$995K	﹤0.01%	2281

Other funds holding MRTX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Russell Frank Company's MRTX Position: Q1 2016 in Review

Russell Frank Company sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2016, closing a stake of 24,343 shares — an estimated $743K sold.

Russell Frank Company first reported a position in MRTX in Q2 2015 and held it in 3 quarters. The position peaked at $1.06M in Q2 2015. 68 funds tracked by Wall St. Rank hold MRTX as of Q1 2016.

Russell Frank Company reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2016 after selling out during the quarter.
Russell Frank Company sold 24,343 Mirati Therapeutics, Inc. Common Stock shares in Q1 2016, an estimated $743K.
Russell Frank Company first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2015 and held it in 3 quarters.
Russell Frank Company's Mirati Therapeutics, Inc. Common Stock position peaked at $1.06M in Q2 2015.
68 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.